PRISYS Biotech has installed an intraprocedural MRI (iMRI) system, the first iMRI-guided delivery system installed in Asia. The system supports brain targeting and micro-infusion with monitoring throughout stereotactic surgical procedures.
The company specializes in non-human primate (NHP) models, and the system was installed earlier this year to support work on therapeutic efficacy and safety in complex neurological conditions.
Precision and Expertise
Working with international specialists, PRISYS Biotech has established iMRI procedures for targeting deep brain structures. That precision matters for structure-specific diseases, where delivery into a defined region changes what a therapeutic can do at the target.
Optimizing Therapeutic Delivery
Infusing a therapeutic directly into a targeted brain region bypasses systemic delivery routes, which lowers the risk of systemic toxicity and off-target effects. Placing the dose inside a specific structure also changes the relationship between dose and local exposure.
Advanced Technology for Advanced Solutions
The iMRI system works with delivery devices built for Cell & Gene Therapies. Low-volume administration, multiple target sites, and single or repeated injections are all supported within the same workflow, which broadens the dosing options available for neurological targets.
Facilitating Translational Research
An iMRI workflow inside a drug development pipeline shortens the path from preclinical studies to clinical trials. The same workflow covers human procedures, device optimization, target validation, pharmacological studies, and endpoint evaluations, so each stage can be checked against a defined scientific standard.
Driving Innovation Forward
PRISYS Biotech continues to develop iMRI procedures alongside the surgical and scientific expertise that runs them. The platform stays in use for structure-specific targets across the CNS.
More detail on the iMRI platform and on recent CNS drug research is available on the PRISYS Biotech website.
Recent Breakthroughs in Gene Therapy for reference
Recent gene therapy work has reported progress in treating neurological disorders:
- AMT-130 IA Update: The update covers development of AMT-130 as a gene therapy for a neurological condition, with an emphasis on targeting disease mechanisms.
https://www.uniqure.com/assets/uploads/AMT-130-IA-update-July-2024.pdf
- Bayer's AB-1005 for Parkinson's Disease: Bayer's investigational therapy AB-1005 has received FDA Fast Track designation for its potential in treating Parkinson's disease. AB-1005 is a gene therapy directed at specific disease pathways.
https://www.bayer.com/media/en-us/askbio-receives-fda-fast-track-and-mhra-innovation-passport-designations-for-ab-1005-investigational-gdnf-gene-therapy-for-parkinsons-disease/
